Abstract
BackgroundPhase III clinical trials are pivotal for evaluating therapeutics, yet a concerning failure rate has been documented, particularly impacting oncology where accelerated approvals of immunotherapies are common. These failures are...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have